

The Synergy of AI and Drug Delivery: A Revolution in Healthcare

Francis-Dominic Makong Ekpan^{1*}  | Merit Oluchi Ori²  | Humphrey Sam Samuel³  | Odii Peter Egwuatu⁴ 

¹Department of BioTechnology Federal University of Technology Owerri, Nigeria

²Department of Microbiology Federal University of Technology Owerri, Nigeria

³Department of Chemical Sciences, Federal University Wukari, Taraba State, Nigeria

⁴Department of Anatomy, Ebonyi State University, Abakaliki, Nigeria

*Corresponding Author E-mail: ekpanfrankdominic3@gmail.com

Received: 2023-10-26, Revised: 2023-12-03, Accepted: 2023-12-15

Abstract

Artificial intelligence (AI) technology has garnered increasing attention in the last ten years due to its potential applications in biological or genetic data analysis, drug discovery acceleration, and the identification of rare or selected molecules. AI has become a disruptive force in the healthcare industry, providing creative ways to improve medicine delivery systems. AI-driven medication delivery systems optimize drug administration, leading to better therapeutic outcomes using machine learning algorithms and data-driven insights. The crucial role of artificial intelligence in medication delivery is examined, which also highlights how AI may improve drug formulation, precision dosage, and personalized medicine. By lowering side effects, raising treatment efficacy, and opening the door for the creation of innovative medications, the combination of AI with drug delivery holds the potential to completely transform the healthcare industry through various applications in personalized medicine, targeted drug delivery, drug formulation, optimization and improving efficiency, etc.

Keywords: Artificial intelligence (AI), Drug delivery, Drug efficacy.

Introduction

A game-changing advancement in the healthcare industry is the use of artificial intelligence (AI) into drug administration, which presents innovative and unprecedented opportunities or options for individualized treatment regimens. To create treatment plans that are uniquely suited to each patient, AI may use a

tremendous amount of patient data, including genetics, medical history, lifestyle factors, and real-time physiological data; however, there are some ethical considerations and privacy concerns associated with the use of such vast patient data, informed consent is crucial for trust, while the volume of data increases the risk of unauthorized access. Security measures are necessary to protect sensitive health information.

Biases in AI algorithms can lead to biased treatment protection measures. This customization includes aspects like medicine selection, dosage, delivery schedule, and even drug composition. As a result, patients might anticipate receiving therapies that are not only more effective, but also have fewer adverse effects, which could improve treatment compliance [1].

AI-driven solutions are streamlining and expediting a process that has historically been time-consuming and expensive in the field of medication research and development. To quickly identify prospective medication candidates, machine learning algorithms can quickly examine huge datasets of chemical substances, biological interactions, and clinical trial findings. AI-driven simulations make it possible to forecast how drugs will interact with the human body, which greatly cuts down on the time and money needed for pre-clinical and clinical research. As a result, a dramatic revamp of the customarily cumbersome process of bringing new drugs to market is imminent. The ability of AI-driven drug delivery to optimize therapeutic formulations is one of its most exciting features. AI has the capacity to build drug delivery systems that optimize therapeutic advantages while reducing side effects, whether it's tweaking the makeup of a chemotherapy treatment to limit damage to healthy cells or fine-tuning the time of insulin delivery to regulate blood glucose levels. This degree of specificity and personalization has the potential to revolutionize chronic disease care and make it easier for patients and physicians to handle. The path to this future is complicated ethically, though. Data privacy and security is at the heart of these worries. By their very nature, AI systems need access to enormous amounts of medical data, which raises serious concerns regarding the data

security and confidentiality. It is crucial to make sure that strong security measures are in place to guard against breaches and improper usage of sensitive patient data. In addition, compliance with data protection laws, such as the General Data Protection Regulation (GDPR) in the European Union or the Health Insurance Portability and Accountability Act (HIPAA) in the United States, becomes crucial [2].

The topics of fairness and bias are another ethical concern. When educated on biased data, AI systems have the potential to reinforce and even exacerbate these biases in their decision-making. This can lead to unequal access to healthcare or differences in treatment recommendations in the context of drug distribution. It is morally necessary to create AI systems that are acutely conscious of these biases and provide countermeasures. To ensure fairness, regular audits and assessments should be a component of the development and implementation of AI. In addition to raise ethical questions, the incorporation of AI into medicine delivery calls for a strong regulatory framework. Obtaining approval from regulatory organizations like the Food and Drug Administration (FDA) in the United States is one of the key regulatory consequences. Clinical validation is a crucial part of regulation, and industry standards and regulatory agencies must set up systems to monitor the moral application of AI to medicine delivery [3].

The emphasis on worldwide availability and affordability is expected to grow as AI-driven medicine delivery progresses. Healthcare inequalities within and between countries are a critical problem. In particular in impoverished areas, regulatory frameworks should stress equitable access to AI-enhanced healthcare advances. The healthcare workforce and the overall economy may be impacted by

the incorporation of AI into drug distribution. The healthcare and pharmaceutical industries may experience employment displacement as a result of the automation of some processes, such as the production and administration of medications, AI and automation may streamline processes, but reduce manual tasks. Telemedicine and digital health solutions may shift traditional roles, while biotechnology and personalized medicine may require different skills set. To address potential workforce issues and enable a seamless transition to an AI-enhanced healthcare system, regulatory and policy measures should be investigated [4].

The aim of this study is to understand the potential of artificial intelligence in revolutionizing drug administration, with a focus on improving precision, efficiency, and safety of drug administration by leveraging AI algorithms to tailor treatments to individual patients' needs. This study explores the integration of AI algorithms in drug delivery systems, their potential for precision medicine, smart drug formulations, safety, regulatory compliance, cost-effectiveness, patient adherence, and disease-specific applications. It also explores potential challenges and limitations, as well as future developments in AI-driven drug delivery systems. From the article we delved into, The role of Artificial Intelligence (AI) in drug delivery, machine learning algorithms, and models for drug delivery optimization, AI application in personalized medicine and targeted drug delivery, smart drug delivery devices enabled by AI, drug formulation and optimization, robotics and automation in AI-driven drug delivery systems, data sources and integration, case studies and clinical applications, challenges and considerations in implementing AI-driven drug delivery, ethical and

regulatory implications of AI in drug delivery, future prospects and advancements in AI-driven drug delivery.

Role of AI in Drug Delivery

Computational pharmaceuticals, which strives to improve medication delivery processes by utilizing multiscale modelling methodologies, was developed as a result of the integration of AI and big data in the pharmaceuticals area. To analyze massive datasets and forecast medication behavior, computational pharmaceuticals uses machine learning and AI algorithms. Researchers can analyze different scenarios and optimize medication delivery systems without the need for protracted trial-and-error studies by simulating the drug formulation and delivery processes. This shortens the needed time for drug development, lowers expenses, and boosts production [5].

Modeling drug delivery systems at various sizes, from molecular interactions to macroscopic behavior, is a key component of computational pharmaceuticals. To forecast drug behavior at each scale, AI algorithms may analyze intricate correlations between drug characteristics, formulation elements, and physiological parameters. This makes it possible to comprehend drug delivery mechanisms more thoroughly and makes it easier to create effective drug delivery systems. It aids in the prediction of the medication's stability, *in vitro* drug release profile, and physicochemical qualities. Along with *in vivo-in vitro* correlation research, the same technology is used for a better evaluation of *in vivo* pharmacokinetic characteristics and drug distribution. Researchers can discover potential hazards and difficulties related to medication delivery systems early in the development process by using the appropriate collection of AI technologies.

This enables proactive adjustments and tweaks to reduce hazards and improve drug performance. The application of AI and computer modelling decreases the reliance on time-consuming and expensive trial-and-error trials, minimizing the likelihood of unexpected results [6].

AI for Nanomedicine

Researchers working in nanomedicine can hasten the creation of novel nanoscale therapies, progress personalized medicine, and improve diagnostics using AI's strengths in data analysis, pattern recognition, and optimization. By providing precise and focused therapeutic techniques at the nanoscale, AI in nanomedicine has the potential to completely transform healthcare using sophisticated algorithms and simulations to achieve precision in nanoscale medicinal approaches, it can analyze large datasets, identify molecular interactions, and optimize therapeutic parameters based on unique patient features, enabling precise and customized treatments [7].

Targeted medicine delivery, imaging, and sensing all involve nanoparticles. AI algorithms can help in nanoparticle design and optimization by foretelling their physicochemical characteristics, stability, and effectiveness. This aids scientists in creating nanoparticles with the appropriate properties for certain purposes. In particular for the treatment of cancer patients, nanomedicines are employed efficiently as drug delivery carriers for medications or medication combinations based on the idea of pharmacological synergy. They include crucially important inputs such as medication, dosage, and stimuli-responsive material selection. The application of a deep learning algorithm for melanoma has demonstrated excellent accuracy in patient care and

support for diagnostic procedures. The behavior and interactions of nanoscale materials in biological systems can be modelled by AI algorithms. This makes it possible to predict the behavior of nanoparticles, the kinetics of drug release, and potential toxicity, helping the creation of secure and efficient nanomedicine formulations. For the real-time monitoring of biomarkers, drug levels, or illness development, AI can be included into nanosensors and biosensors. These sensors can give healthcare professionals constant input, enabling prompt interventions and individualized treatment adjustments. The AI-based database is helpful for automating the scaling up of nanocarriers. In order to optimize nanocarriers and test for medication compatibility using computational methods, AI is also applied in nanocarrier drug delivery systems. The evaluation of drug loading, formulation stability, and drug retention are all done using these methods. As a result, AI involvement helps to improve the therapeutic nanocarriers needed for particular cell types to treat tumors. Yuan He *et al.* investigated the use of machine learning techniques to predict nanocrystals made using the wet ball milling process and high-pressure homogenization. Combining computational methods such as Monte Carlo simulations and molecular dynamics with theoretical methods can reduce the need for repeated tests. In crucial experiments, the simulation techniques are useful for quantitative measurements. In addition, AI is used to build the necessary database repository for nanocarriers, which aids in the determination of 3D structures as well as analyses of physical and chemical properties in conjunction with structural nanobiology. To study the connection between nanocarrier shape and toxicological, physical, and biological data, such archives are necessary.

Another study by Lutz Nuhn on the use of AI for improved analysis discovered that AI was able to identify the heterogeneous vascular permeability for systems designed to deliver drugs utilizing nanoparticles. To properly investigate cancer medicine, Zhoumeng Lin *et al.* applied AI for better assessment with a PBPK modelling approach. The same is beneficial to learn more about the reasons for limited nanoparticle tumor delivery efficacy [8].

AI Application for Parenteral, Transdermal, and Mucosal Route Products

Artificial intelligence (AI) can be used to develop and produce injectables, biologics, and other challenging formulations. AI systems that predict complex physicochemical factors for medication formulation could aid in formulation development. AI models examine formulation elements, excipients, and manufacturing procedures to optimize pH, solubility, stability, and viscosity. As a result, parenteral formulations are made more stable. AI can enhance the production of parenteral products in terms of their quality, efficacy, and variability. AI systems can find process variables that affect product quality and recommend appropriate modifications by looking at real-time process data. Batch failures, product homogeneity, and manufacturing output all increase as a result. AI algorithms may find patterns and variances in product quality in large datasets from analytical testing, such as particle size analysis, spectroscopy, and chromatography. By making it possible to identify and address quality problems early on, this ensures high-quality products. Using past data and process variables, AI models can predict contamination, stability, and regulatory deviations. During the production of parenteral products, AI-based

monitoring systems may analyze significant process parameters in real time. By merging data from sensors, instruments, and process controls, AI systems can spot anomalies, foresee deviations, and act quickly. As a result, product quality is preserved, and noncompliance is reduced. For complex parenteral product manufacturing equipment, AI streamlines maintenance procedures. To foresee equipment failure or deterioration and schedule preventive maintenance, AI models examine sensor data, equipment performance history, and maintenance records. This increases productivity, decreases maintenance, and prevents needless downtime. Parenteral and sophisticated biological product regulation compliance can be supported by AI. By examining process data and product characteristics, AI algorithms may evaluate compliance, identify potential noncompliance issues, and offer suggestions for process improvement. This promotes adherence to GMP standards and legal requirements [9].

To determine if the particles were swimming, sinking, or sticking into the inner edge of the container, for instance, AI was employed to inspect the particles. It was advised to use the optical setup, strategy, algorithm, and inspection to properly inspect the individual particles. The floating particles were examined using the particle tracking technique and image subtraction. The liquid inside the container is free to move, allowing high-resolution photographs to capture the behavior of the moving particles and artificial intelligence (AI) to track the direction of the particles' motion. The proper particle isolation is further accomplished using the deep learning technique. One of the greater issues associated with parenteral batch flaws is bubble formation, which is normally not harmful to patients, but there is a great need to distinguish between particles and bubbles. The AI-based image

processing type of algorithm was used for these types of visual inspection and the issues associated with them. Surface crack detection using Surface Qualifiers 7500, which analyses hundreds of millions of data points per second with the use of graphical processing subunits, was one of the other camera-based AI applications. Using AI data analysis, pattern recognition, and predictive modelling, manufacturers may enhance product performance, reduce manufacturing risks, and produce safe and efficient parenteral and technologically sophisticated pharmaceutical products. The study emphasizes the interpretability of Machine Learning (ML) models, which can provide insights into the decision-making process. Bannigan et al. highlight the availability and potential of cutting-edge machine learning (ML) technologies in the field of pharmaceutical and materials science. They demonstrate that ML can accelerate the development of innovative drug delivery technologies by accurately predicting *in vitro* drug release from long-acting injectables (LAIs).

To spur the development of more sophisticated and specialized ML techniques in the future, the study provides a proof of concept for ML in drug formulation. The traditional trial-and-error method of developing ocular, transdermal, pulmonary, and other mucosal drug delivery systems is ineffective for complicated formulations because it lacks a thorough understanding of the process.

Though new opportunities have emerged as a result of recent developments in computational pharmaceuticals, particularly those in machine learning and multiscale simulations. Product development has become more effective as a result of recent advancements in the use of molecular simulations, mathematical

modelling, and PK/PD modelling for these drug delivery methods. By offering in-depth insights and supporting logical formulation creation, *in silico* modelling and simulations offer special benefits. In the era of Pharma 4.0, integrating *in silico* techniques, resolving data issues, and collaborating across disciplines might result in more effective and goal-oriented drug formulation design [10].

AI Tools for Biologics Product Development

Newer proteins, peptides, nucleic acid biologics, and immunotherapeutic are made possible by AI. AI algorithms might make it easier to create proteins and peptides with specific properties such as enhanced stability, binding affinity, and solubility. By examining vast amounts of data on protein structure and function, AI models may create therapeutic sequences that have improved stability, binding affinity, or immunogenicity. This makes it possible to create customized biologics that are safer and more effective [11].

AI systems can use clinical, proteomic, and genomic data to identify medicinal targets. By identifying disease targets, AI enables researchers to create protein and peptide biologics that change biological pathways or target proteins that cause disease. Protein folding can be predicted by AI models using amino acid sequences. Protein folding is necessary for comprehending protein function and developing optimized biologics. To create stable and functional biologics, deep learning and molecular dynamics simulations can predict protein folding patterns. Protein/peptide-target molecule binding affinity is predicted by AI algorithms. Using large protein-protein or protein-peptide datasets for training, AI models can accurately assess binding strength. By selecting or developing biologics with a high affinity

and specificity for targets, this increases therapy effectiveness. Formulations for protein and peptide biologics may be improved with the use of AI. Biologic quality and effectiveness are influenced by formulation variables, aggregation propensity, and stability. By examining protein physicochemical properties, formulation ingredients, and manufacturing processes, AI algorithms can improve formulation conditions, biologic stability, and shelf life. AI algorithms forecast the biological toxicity of proteins and peptides. By examining structure-activity connections while being educated on toxicological datasets, AI systems can predict immunogenicity and unfavorable biologic consequences. This enables scientists to identify and change dangerous sequences or structures. Clinical trials for protein and peptide biologics are being optimized using AI. Using information about the patient, the ailment, and the treatment results, AI algorithms are capable of anticipating patient responses and improving trial methods. Patient recruitment, research planning, and individualized care are all made easier as a result. Exosome, CAR T-cell, and CRISPR/Cas9 research, diagnostics, and therapies have the potential to be considerably improved by AI [12].

AI in Medical Devices

A medical device can be used alone or in combination with software or other related systems in vitro to treat a patient's medical problems. It is a type of apparatus, implement, instrument, implant, or machine appliance for specialized medical applications. AI has significantly improved medical gadgets, revolutionizing healthcare in a number of ways.

Due to the pandemic, remote health monitoring and personalized treatment have become crucial and widely used in

many countries, which has accelerated the use of AI and machine learning in the healthcare industry. The following are some instances of how AI is used in medical equipment:

Diagnostic Assistance

Medical imaging data from X-rays, CT scans, and MRIs can be analyzed by AI algorithms to help medical personnel identify and diagnose disorders. For instance, AI-powered algorithms can support the anomalies detection in electrocardiograms (ECGs) or malignant lesions in medical imaging.

Remote Monitoring

AI-enabled medical equipment can track vital signs and other important metrics while remotely monitoring the health situations of patients. Patients with chronic diseases can benefit the most from this because they can receive individualized care in the convenience of their own homes. Healthcare providers can receive alerts or insights from AI algorithms once they analyze the collected data.

Wearable Devices

Wearable tech includes AI in the form of smart watches, activity trackers, and biosensors. These gadgets can keep an eye on a variety of health indicators, including blood sugar levels, sleep habits, and even heart rate. AI algorithms assist in the interpretation of the data and offer people practical knowledge for enhancing their health and wellbeing. AI is employed in sophisticated prosthetic devices to enable more natural movement and functionality in the fields of prosthetics and rehabilitation. Machine learning algorithms can adjust the prosthetic to better fit the user's intentions by learning from their movements. AI can also help with rehabilitation by analyzing motion and

giving patients feedback to help them move better and track their progress.

Surgical Assistance

Artificial intelligence (AI) has found use in surgical tools to support surgeons during operations. Robotic surgical devices, for instance, use AI algorithms to help surgeons carry out precise and least intrusive treatments. To provide real-time guidance and enhance surgical outcomes, AI can also analyze preoperative and intraoperative data.

Medication Management

AI-powered devices can assist patients in efficiently managing their medicine. Smart pill dispensers can track adherence, distribute the right dosage, and remind patients to take their pills on schedule. To provide individualized suggestions for medication management, AI algorithms can also analyze patient data, including medical history and medication usage [13].

These illustrations show how AI is incorporated into medical equipment to improve patient care, monitoring, and diagnosis. The use of AI results in more precise diagnoses, better treatment outcomes, and better healthcare delivery because of its capacity to analyze massive volumes of data, spot trends, and offer personalized insights. To entice big enterprises and expand the potential for business in the healthcare sector, it also helps to develop innovative products for the benefit of patients and efficiently reach out to new client categories. Currently, medical technology-based businesses are utilizing AI in key areas like diagnosis, prevention, and care, as well as patient-specific personalized medicine. For instance, the international medical technology company Medtronic has created cutting-edge AI applications to assist patients with diabetes in properly managing their disease. One

standout is the Medtronic Guardian Connect system, which uses AI and continuous glucose monitoring (CGM) technology to give people with diabetes real-time information and support. The Medtronic Sugar IQ app, which acts as a mobile personal assistant for those managing diabetes, was created in 2016 in partnership with IBM Watson. This software uses artificial intelligence (AI) to offer useful features for managing diabetes effectively. "Insights" is one of the main components of the Sugar IQ app. The programme tracks the user's glucose patterns over time, looks for trends, and sends the patient customized messages and notifications. These perceptions assist people in comprehending how particular behaviors, practices, and environmental elements affect their blood glucose levels. Users can make wise judgements and take proactive measures to better control their diabetes by getting this insight. "Glycemic assistance" is the Sugar 444Q app's second crucial feature. Based on users' most recent glucose measurements, the app uses AI algorithms to offer real-time advice and suggestions. The app can offer suggestions for steps to help the user maintain a more stable glucose range if the glucose levels are trending high or low. This function serves as a virtual assistant, offering individualized support and reminders to aid users in selecting the best options for their diabetes care. The Sugar IQ app also features a "food logging" feature. Through the app, users may keep track of their carbohydrate intake and document their meals. The software can then analyze how different foods affect blood glucose levels and offer details about how particular meals or food selections affect blood sugar. With the use of this knowledge, people can make better food choices that will improve their glycemic control. The Medtronic Sugar IQ app provides useful

tools for people with diabetes by fusing AI technology with glucose monitoring and personalized messages. It supports users in making well-informed decisions regarding nutrition and lifestyle choices, offers real-time aid in managing blood sugar levels, and helps users obtain insights into their glucose patterns. These characteristics help individuals better control their diabetes and lead to better disease management [14].

Machine Learning Algorithms and Models for Drug Delivery Optimization

Medication distribution systems are optimized, and medication development choices are improved, using machine learning algorithms. These models can prioritize and optimize lead compounds, predict the pharmacokinetics and toxicity of therapeutic candidates, and eliminate the need for extensive animal testing. AI algorithms that analyze actual patient data can also support personalized medical methods, improving patient adherence and the effectiveness of treatments. A field called computational pharmaceuticals uses multiscale modelling techniques to improve medication delivery systems. To analyze massive databases and forecast drug behavior, machine learning and AI algorithms are used. Researchers can analyze different scenarios and optimize medication delivery systems without the need for protracted trial-and-error studies by simulating the drug formulation and delivery processes. This shortens the time needed for drug development, lowers expenses, and boosts productivity. Machine learning techniques enhance drug discovery decision-making in a variety of areas, including QSAR analysis, hit discoveries, and therapeutic concepts. Some of the frequently utilized models for data analysis and prediction in drug development include support vector

machines, random forests, and multilayer perceptron [15].

Machine learning algorithms can be used to forecast the release of investigational drugs from cutting-edge drug delivery devices, like long-acting injectables, according to recent studies. To cut down on the time and expense involved in developing novel medication formulations, these trained models can be used to direct the creation of new long-acting injectables. In general, machine learning algorithms are demonstrating to be a useful tool in drug development and delivery optimization decisions. They can optimize medication formulations, forecast drug behavior, and lessen the need for expensive animal testing, which will improve patient outcomes and boost output.

Application of AI in Personalized Medicine and Targeted Drug Delivery

Personalized medicine and tailored drug administration may be revolutionized by artificial intelligence (AI). Here are some ways that these fields could use AI:

1. The development of personalized medicines: AI can be extremely helpful in the clinical development and implementation of new personalized health products at all pertinent stages. AI can assist in identifying the best intervention targets, evaluating their usefulness, and improving the relevant assays and methods for collecting, storing, aggregating, and integrating the data they generate.

2. Precision medicine: AI can help in finding solutions to challenging issues in individualized care. For instance, AI can recognize phenotypes, take genomics into account when developing therapies, and forecast how chemotherapy would affect a patient's reaction. In addition, AI can build medication delivery devices and systems that increase patient

adherence and convenience, as well as improve localized drug administration systems capable of biomarker sensing [16]. AI may also analyze real-world patient data to optimize drug formulations and delivery systems.

3. Identifying the right pharmacological target in the organism, creating the right molecule to interact with it, and determining which populations the molecule has the most chance of being effective are all made possible by AI. Researching novel drugs can take less time and money thanks to AI.

4. Therapeutic intervention and drug design: For therapeutic intervention and drug design, AI methods are cutting edge. There are currently 51 FDA-approved targeted gene-specific medications for mental and neurological disorders. The main goal of the development of sequencing technology has been to accelerate the adoption of early precision diagnoses. The development of precise treatments for neurodevelopmental diseases is still very difficult [17].

Smart Drug Delivery Devices Enabled by AI

The field of drug delivery has witnessed significant advancements in recent years, with the integration of Artificial Intelligence (AI) playing a pivotal role in revolutionizing drug administration systems. Smart drug delivery devices, empowered by AI, offer precise and personalized medication administration, improving patient outcomes, enhancing adherence, and minimizing side effects. Artificial Intelligence, particularly machine learning and deep learning algorithms, has empowered drug delivery devices by enabling them to make informed decisions, optimize drug release, and monitor patient responses. This is achieved through the analysis of patient

data, drug properties, and real-time feedback, ensuring a dynamic and adaptive drug administration process.

One of the most significant benefits of AI-driven smart drug delivery devices is their ability to support precision medicine. By leveraging AI to analyze a patient's genetic, physiological, and environmental data, these devices can tailor drug dosages and schedules to meet individual patient needs [18]. This approach not only maximizes therapeutic efficacy, but also minimizes adverse effects. AI algorithms can adapt drug release profiles based on real-time patient data. For instance, insulin pumps for diabetes management use AI to predict blood glucose levels and release insulin accordingly. This ensures better glycemic control and minimizes the hypoglycemia risk.

Poor medication adherence is a common issue in healthcare. AI-powered devices offer features like reminders, tracking, and feedback to improve patient compliance. By incorporating behavioral insights, these devices motivate patients to adhere to their medication regimens, leading to better health outcomes. AI-enabled drug delivery devices can continuously monitor patient responses, adjusting drug administration as needed. For instance, smart inhalers can analyze inhalation patterns, detect inhalation errors, and provide immediate feedback to patients. This real-time feedback loop ensures that the medication is being used correctly. AI in healthcare raises concerns about data security and patient privacy. It is essential for smart drug delivery devices to comply with stringent data protection regulations, such as HIPAA in the United States and GDPR in the European Union.

Drug Formulation and Optimization: Advances in Pharmaceutical Science

The field of drug formulation and optimization is fundamental to the pharmaceutical industry, as it plays a crucial role in developing safe and effective medications for patients. Researchers and scientists continually strive to create optimized drug formulations that enhance drug efficacy, improve patient compliance, and reduce side effects.

Rational drug formulation design involves a systematic approach that considers the physicochemical properties of the drug, dosage form, and patient needs. Researchers employ computational tools, such as molecular modeling and simulations, to predict the behavior of drug molecules in different formulations. This approach enables the formulations design that maximizes drug solubility, stability, and bioavailability. Nanotechnology has opened new avenues for drug formulation optimization. Nanoparticles and nanocarriers can enhance drug solubility, target specific tissues, and provide controlled release. These nano-formulations have the potential to improve drug delivery and reduce side effects, as demonstrated in various studies. Advancements in drug formulation have also contributed to the concept of personalized medicine. Tailoring drug formulations to individual patient characteristics, such as genetics or metabolism, can optimize treatment outcomes. This approach has shown promise in oncology, where personalized cancer therapies are becoming more prevalent. Optimizing drug formulations is not limited to novel drugs. Drug repurposing, or the use of existing drugs for new indications, is gaining traction [19]. Optimizing the formulation of repurposed drugs can lead to novel treatments for various diseases.

Furthermore, combining multiple drugs into a single formulation can enhance therapeutic outcomes while minimizing side effects. The pharmaceutical industry is increasingly adopting green chemistry principles to optimize drug formulations. Environmentally friendly practices, such as reducing waste and using safer solvents, can lead to more sustainable and efficient drug development.

Robotics and Automation in AI-Driven Drug Delivery Systems

The intersection of robotics, automation, and artificial intelligence (AI) has catalyzed remarkable advancements in the realm of drug delivery systems. AI-driven drug delivery systems integrated with robotics and automation offer unparalleled precision, efficiency, and safety in medication administration.

Robotic Drug Dispensing and Administration

Robotic systems, equipped with AI algorithms, are now capable of dispensing and administering medications with unparalleled accuracy. These robots can precisely measure and mix medications, thereby reducing human errors in the preparation of drug formulations. Moreover, they can administer medications to patients following precise dosage instructions, significantly reducing the risk of under- or overdosing.

Autonomous Medication Management

AI-driven drug delivery systems with robotic components can autonomously manage medication schedules for patients. These systems can store, organize, and dispense medications at the right time, ensuring that patients adhere to their treatment regimens. This autonomous approach is particularly beneficial for patients with complex

medication schedules or those who require constant monitoring [20].

Intricate Drug Delivery Techniques

Robotics and automation enable the development of intricate drug delivery techniques. For instance, micro-robots or nanobots can navigate through the human body, targeting specific cells or tissues for drug delivery [21]. This precision level allows for the localized treatment of diseases, reducing systemic side effects.

Telemedicine Integration

AI-driven drug delivery systems with robotics can be seamlessly integrated into telemedicine platforms. Telemedicine allows healthcare professionals to remotely monitor and control medication administration for patients. This approach is particularly

valuable for patients in remote or underserved areas [22]. The concept of telemedicine and its associated services has become firmly established and demonstrated to be of significant societal benefit. As depicted in Figure 1, telemedicine encompasses a range of features and facilities tailored for the healthcare sector. It encompasses chronic health management, adherence to prescriptions, remote services, and comprehensive care for critical and severe cases, among other offerings. These attributes collectively empower telemedicine to make valuable contributions to the healthcare and medical care domains. Furthermore, a selection of tele-wearables aids in patient recovery and provides them with real-time updates on their health status in an innovative manner.




Figure 1 Various capabilities & features of telemedicine for healthcare domain [22]

Enhanced Patient Safety

Robotics and automation in drug delivery systems contribute significantly to patient safety. AI algorithms can detect potential drug interactions, allergies, and contraindications, ensuring that patients receive medications that are safe and compatible with their medical history. In addition, robotic systems can alert

healthcare providers in real-time in case of any adverse events during drug administration.

Data Sources and Integration

Data from various sources is used in the development and operation of an AI-driven medicine delivery system. For the system to function effectively, numerous

data sources should be integrated. The pharmaceutical industry is only one of many areas of society where artificial intelligence (AI) is being used more and more. The pharmaceutical industry has used AI in many different areas, including medication development and discovery, drug repurposing, increasing productivity in the industry, clinical trials, and more. The pharmaceutical industry has undergone a revolutionary transition as a result of AI-integrated medication research and development, which has boosted industry growth. Data digitization in the pharmaceutical industry has dramatically increased during the last few years [23]. To answer challenging clinical problems, it is difficult to acquire, examine, and apply this knowledge as a result of digitalization. This encourages the AI usage since it can manage massive amounts of data with improved automation. A technology-based system called artificial intelligence (AI) uses various cutting-edge tools and networks to simulate human intelligence. However, it does not totally threaten to take the place of human physical presence. To achieve certain goals, AI makes use of hardware and software that can comprehend and learn from the input data. As mentioned in this review, its applications in the pharmaceutical industry are constantly being expanded. The McKinsey Global Institute predicts that the rapid advancements in AI-guided automation would likely radically alter society's work culture. To find existing medications with potential as therapeutics for various ailments, AI algorithms can examine large-scale biomedical data. AI is further used to predict medication release kinetics and absorption profiles, optimize drug formulations and delivery systems, and build convenient and effective drug delivery methods. AI-based nanorobots for drug delivery that are primarily made

up of integrated circuits, sensors, power supplies, and secure data backup have been developed. The deal between Valo Health and Novo Nordisk also calls for the discovery and creation of innovative therapies for cardiometabolic disorders based on Valo's extensive human dataset and AI-powered computation. By facilitating a better understanding of target biology and processing vast volumes of data with improved automation, AI has the potential to positively benefit medication research and development. The creation and operation of an AI-driven medicine delivery system depend heavily on the integration and efficient management of these data sources. When working with sensitive healthcare data, data security, and privacy concerns, as well as regulatory compliance, are particularly crucial [24]. Several important data sources and factors for integration in an AI-driven medicine distribution system are listed below:

1. Electronic health records (EHRs), medical histories, genetic information, and patient demographics are all examples of patient health data. The AI system may tailor drug administration depending on a person's unique medical needs by integrating patient health data.

2. Biometric Information: Information on a patient's health status can be obtained in real-time using data from wearable sensors and devices like heart rate monitors, glucose meters, and activity trackers. Biometric data integration allows for dynamic drug dose modifications.

3. Pharmacological Databases: For the AI system to make wise decisions about drug distribution, comprehensive databases of pharmacological properties, interactions, side effects, and pharmacokinetics are necessary.

4. For the AI system to select the best delivery mechanism, information regarding drug formulations, such as

solubility, stability, and release profiles, is essential.

5. Drug Interaction Databases: Knowledge of possible drug-drug interactions is essential to ensuring that the AI-driven system does not combine potentially dangerous drugs [25].

6. Sensor Data: Data from embedded sensors in medication delivery systems, such as intelligent inhalers or insulin pumps, can offer real-time feedback on patient response and consumption.

7. Environmental Data: Environmental aspects that can affect medicine delivery include air quality and pollution levels. By incorporating environmental data, the system is able to modify medicine administration in response to environmental factors.

8. Research Literature: Clinical guidelines and research papers that are regularly updated in the medical and pharmaceutical literature are a helpful resource.

9. Production and Quality Assurance Data: Data from the quality assurance and drug manufacturing processes can guarantee that the drug delivery system performs to the greatest possible levels of safety and quality.

10. Data used to train the AI models within the medication delivery system, such as previous patient data and clinical trial findings, must be integrated for the system to learn and make decisions. This is known as machine learning and artificial intelligence (AI) model training data, as depicted in Figure 2 [26].




Figure 2 AI- models in Drugs delivery [26]

Case Studies and Clinical Application

Drug efficacy, patient outcomes, and treatment personalization can all be enhanced by AI-driven drug delivery systems, which have the potential to completely transform the healthcare industry. AI-driven drug delivery systems have a wide range of case studies and clinical applications. Here are some illustrations: For each scale, drug behavior can be predicted using

complicated correlations between drug characteristics, formulation elements, and physiological parameters analyzed by AI systems. This enables a more thorough understanding of drug delivery mechanisms and helps in the development of effective drug delivery systems. Drug delivery nanorobots powered by AI have been created, and they primarily consist of integrated circuits, sensors, power supplies, and

secure data backup. In a partnership, Valo Health and Novo Nordisk will use Valo's extensive human dataset and artificial intelligence (AI)-powered computation to find and develop new treatments for cardiometabolic disorders. To run fewer, more effective trials in the lab and generate the same number of leads, AI can assist in identifying the most promising drugs and targets at every stage of the value chain. Over the past ten years, the AI-driven drug discovery business has expanded dramatically due to new competitors, significant capital investment, and technical maturation [27].

An AI-driven system is used by a mental health clinic to combine data from wearable biometric devices, patient self-reports, and medication adherence. This data is analyzed by AI algorithms to modify mental drug schedules. By adjusting medicine dosages in accordance with patient responses and changes in their mental health, AI-driven medication management improves the effectiveness of mental health treatments. However, pediatric hospitals use AI algorithms to calculate the best medicine dosages for children based on their age, weight, genetics, and clinical status. On the basis of physiological changes, the system delivers real-time adaptations. The danger of medication errors is reduced, treatment safety is increased, and age- and weight-appropriate dose is guaranteed with AI-driven pediatric dosing. Hospitals use AI-driven tools to track bacterial resistance trends and prescriptions for antibiotics. The AI guides clinicians in real-time, ensuring the proper dosage of antibiotics. People with chronic pain use wearable gadgets that track their activity, pain levels, and drug responses. AI algorithms recommend individualized pain management techniques. AI-driven pain treatment maximizes pain alleviation,

reduces the need for opioids, and improves patients' quality of life.

These case studies and clinical examples highlight the adaptability and potential advantages of AI-driven drug delivery systems in a range of medical settings, from acute care to the management of chronic diseases. Healthcare professionals may now give more precise and individualized therapies because to AI, which improves patient outcomes and lowers healthcare costs. The identification, optimization, and design of innovative therapeutic candidates could be sped up and accelerated by AI-driven drug delivery systems, which would ultimately result in more effective and efficient pharmaceuticals [28].

Challenges and Considerations in Implementing AI-Driven Drug Delivery

Due to a number of issues, implementing AI-driven drug delivery systems can be difficult. The following difficulties and factors must be considered:

1. **Data challenges:** To build models and make reliable predictions, AI needs a lot of high-quality data. However, the size, expansion, diversity, and unpredictability of the data might provide serious difficulties. For training and validation, AI algorithms require huge, high-quality datasets. Such data could occasionally be scarce or challenging to get. Think about working with medical professionals, academics, and data scientists to guarantee access to pertinent and trustworthy data. To safeguard patient privacy, data sharing agreements and anonymization procedures must be in place.

2. **Infrastructure issues:** The use of AI necessitates a flexible infrastructure that can scale, execute applications, perform data governance, and run data collection. This might prevent certain

pharmaceutical corporations from putting it into practice [29].

3. Ethics-related factors: Ethics issues such as data privacy, bias, and openness are brought up by the use of AI in drug research and development. To guarantee that AI is utilized morally and sensibly, these challenges should be addressed. Privacy and ethical considerations are raised when handling sensitive patient data for AI-driven decision-making. Patients should have faith that their information is secure and being used for their good.

4. Implement effective encryption and data security procedures. Create policies for the usage of data and consent. Give patients access to their data and be open with them about how it is being utilized.

5. Collaboration issues: To find new therapeutic targets and enhance the efficacy of current therapies, collaboration between AI researchers and pharmaceutical experts is crucial. Collaboration; however, can be difficult because of disparities in knowledge, culture, and communication. AI-driven advice should be trusted and understood by healthcare professionals and patients. Adopting AI as a collaborator may encounter resistance or distrust. Provide in-depth instruction on the capabilities and restrictions of the AI system to medical practitioners. Create user-friendly user interfaces to encourage clinician and AI collaboration [107-109].

6. Regulatory obstacles: A current regulatory framework is required to ensure that safe and effective AI devices can quickly reach patients. The regulatory environment for AI-driven medicine delivery systems is continuously changing. In some places, the regulatory process for AI-driven medicine delivery systems may not be well established. Getting regulatory permission can be a difficult and drawn-out procedure [30].

Ethical and Regulatory Implications of AI in Drug Delivery

The application of artificial intelligence (AI) to drug delivery has the potential to completely transform the way that medicine is administered by increasing the accuracy, security, and efficacy of dosing. But this adoption of cutting-edge technology also raises a host of moral and legal issues that need to be carefully considered. In this in-depth investigation, we will delve into the complex web of moral conundrums and legal difficulties involving AI in medicine distribution.

Ethical Implications

1. Data Privacy and Security: Data privacy is one of the most important ethical issues. For AI systems to make wise decisions, they need to have access to patient health data. Protecting this data is essential for maintaining patient privacy and adhering to laws like the General Data Protection Regulation (GDPR) in the European Union and the Health Insurance Portability and Accountability Act (HIPAA) in the United States. It is essential to make sure AI systems are created with strong security measures to prevent data breaches.

2. Fairness and Bias: AI algorithms might pick up biases from the training data. Healthcare disparities may result when these prejudices influence treatment choices. Making ensuring AI systems do not discriminate against particular demographics or socioeconomic categories is morally required. To address bias, regular audits and mitigating measures should be implemented.

3. Explainability and Transparency: Many AI models function as "black boxes," making it difficult to comprehend the justification for their judgments. Transparency and explicability are crucial in the healthcare industry if

patients and healthcare professionals are to believe and accept AI-driven suggestions. It is difficult to strike a balance between sophisticated AI methods and understandable models.

4. Patient Autonomy: AI systems have the potential to limit patient autonomy by influencing treatment choices. When patients are not sufficiently informed about how AI recommendations are generated and if they have the last say in their treatment regimens, ethical issues can develop. Making sure that patients actively participate in making healthcare decisions is essential.

5. Accountability and culpability: Determining accountability and culpability when AI systems are to blame for mistakes or unfavorable results can be difficult. It is necessary to build legal frameworks to solve accountability concerns. To ensure that both healthcare providers and AI developers are held accountable for any errors, it is crucial to identify clear lines of responsibility and liability [31].

Regulatory Implications

1. Regulatory permission: Organizations like the US Food and Drug Administration (FDA) may need to give AI-powered drug delivery systems regulatory permission. For these systems to be safe and effective, strict regulatory compliance is essential. The pathways creation for AI clearance is a huge task as the regulatory environment is continually changing.

2. Clinical Validation: A crucial regulatory problem is ensuring the efficacy and safety of AI-driven medicine delivery systems. To show that AI systems offer real benefits without harming patients, clinical trials, and validation studies must be carried out.

3. Oversight and Accountability: Mechanisms to monitor the moral application of AI in drug distribution

must be established by regulatory organizations and industry norms. To preserve the level of care and patient safety, clear norms, and standards must be used in the development, implementation, and monitoring of AI systems in the healthcare industry.

4. Global Access: The advantages of AI in drug delivery ought to be widely available and reasonably priced. Regulations should be created to guarantee fair access to these breakthroughs, particularly in underprivileged areas.

5. Economic Impact: The introduction of AI into medicine delivery could have an adverse effect on the economy by eliminating jobs in the pharmaceutical and healthcare sectors. To address potential job displacement and enable a seamless transition to an AI-augmented healthcare system, regulatory and policy measures should be investigated [32].

Future Prospects and Advancements in AI-Driven Drug Delivery

The pharmaceutical sector, including drug development, distribution, and discovery, may be completely transformed by artificial intelligence (AI). AI can be used to increase the efficacy and minimize the negative effects of medication delivery methods including inhalers, patches, and implants. AI can also be used to assess patient data and create individualized treatment regimens, which could result in more effective medicines with fewer adverse effects. A speedier medication development process is possible thanks to AI's ability to identify hit and lead compounds. AI can also be used to find new applications for medicines that are already on the market, which helps speed up and lower the price of medication development. AI can help with regulatory compliance and ensure drug safety,

lowering the possibility of unfavorable events and enhancing patient outcomes.

The identification, optimization, and creation of innovative therapeutic candidates have the potential to be streamlined and accelerated by AI-driven methodologies in drug research and development, ultimately resulting in more effective and efficient pharmaceuticals. The quality and appropriateness of data, ongoing assurances of drug safety and efficacy, educating the scientific community to enhance buy-in, and concerns around intellectual property rights are among the difficulties that still need to be resolved [33].

AI-driven drug delivery has great promise for the future, with the ability to revolutionize healthcare by improving the accuracy, safety, and effectiveness of medicine administration. There are a number of promising future developments to look forward to:

1. **Personalized Medicine:** Personalized medicine is a method of treating patients that is specifically designed for them based on their individual traits, such as genetics, environment, and lifestyle. From identifying intervention targets to evaluating their usefulness, artificial intelligence (AI) is essential to the development of tailored therapies. AI is capable of analyzing patient data to create individualized treatment plans that result in more efficient therapies with fewer adverse effects. Furthermore, it can make use of complex computing and inference to produce insights, enhancing clinician decision-making with added intelligence. AI-enabled customized medicine focuses on finding abnormalities based on DNA, medical history, and family history, eliminating guesswork from diagnosis and treatment strategies. Moreover, it enables small firms to spend money on the health and happiness of their employees. However,

issues including data security, privacy, and quality as well as intellectual property rights need to be addressed [34].

2. **Drug Discovery and Development:** AI is accelerating the drug discovery process. Machine learning models can predict potential drug candidates, identify promising molecules, and simulate drug interactions within the body. This reduces the time and cost associated with bringing new drugs to market.

3. **Optimized Drug Formulations:** It is essential to use artificial intelligence (AI) while improving medicine delivery methods and formulations. Drug release kinetics, physicochemical characteristics, and stability can all be predicted using AI models. Artificial intelligence (AI) systems examine intricate connections between drug characteristics and formulation elements, facilitating a better understanding of drug delivery pathways. AI is capable of creating formulations for a wide range of goods, including polymers, vaccines, coatings, adhesives, and more. AI can further forecast the release of experimental drugs from cutting-edge delivery devices. Opportunities to create new materials, inventive formulations, and superior medications can be found by combining computational methods and experimental skills for drug formulation optimization [35].

4. **Real-time Monitoring:** Wearable sensors and dynamic predictive modeling are making real-time monitoring possible, which is essential in personalized care. These sensors' data can be analyzed by AI to spot changes in a patient's condition, cut down on human error, and enable individualized therapy. In addition, these sensors provide continuous drug concentration measurement, lowering toxicity concerns. To track cognitive deterioration and pharmacological

effects, digital endpoints gathered outside of a clinical setting can be employed. Drug distribution can also be modified by AI-powered devices based on current information [36].

5. Nanotechnology and Drug Delivery: Artificial intelligence (AI) can help in the creation of nanoscale drug delivery devices. With the help of nanotechnology, drugs can be released in a targeted and regulated manner at the cellular or even molecular level, reducing adverse effects and increasing efficacy.

6. Telemedicine Integration: Artificial intelligence (AI) is playing a crucial role in telemedicine, improving patient care, reducing administrative tasks, and enhancing healthcare outcomes. AI can deliver remote health care, providing data-driven insights and personalized treatment options. However, challenges like data interoperability, AI talent shortage, and liability concerns need to be overcome. AI can enhance diagnostic accuracy, enable remote patient monitoring, analyze medical images, and provide virtual triage services. To integrate AI into telemedicine, specific use cases need to be identified, and AI algorithms should be integrated into the platform [37].

7. Robotics and Automation: The advancement of robotics and automation in drug delivery systems is greatly aided by AI. AI can create individualized treatment regimens, improve nanorobots for controlled drug delivery, and optimize drug delivery systems. Robotic medication delivery systems have the ability to give pharmaceuticals to specific cells or tissues while AI continuously monitors changes in the patient's state. Automated manufacturing procedures can guarantee product homogeneity and minimize quality standard deviations. Examples include compounding, dosing, and filling. In addition, AI can provide virtual triage or medical counseling services, enable remote patient

monitoring, evaluate medical imagery, and improve diagnostic accuracy. However, issues must be resolved and data quality and relevance should be guaranteed. Robots can precisely and hygienically prepare, handle, and distribute pharmaceuticals, to reduce human error and contamination risks [38].

8. Artificial Intelligence in the Healthcare Ecosystem: A wider AI-powered healthcare ecosystem will include drug delivery systems. Electronic health records, diagnostic equipment, and predictive analytics are all part of this ecosystem, which enables thorough and proactive patient care.

9. Ethical and Regulatory Developments: As AI-driven drug delivery spreads, regulatory bodies will keep improving and adapting their policies to assure its security and moral application. This might involve strong ethical frameworks for decision-making and transparent regulatory procedures for AI technology.

10. Interdisciplinary Collaboration: To advance AI-driven drug delivery, it will be necessary to work with experts from various disciplines, including engineering, computer science, ethics, and medicine. Collaborations and interdisciplinary research will fuel innovation in this field.

11. Clinical Trials Enhanced by AI: AI will be very important in improving clinical trials. Machine learning can be used to find the best patient cohorts, forecast how well patients will respond to therapies, and even create adaptive clinical trials that change as they go along based on current data [39s].

12. Global Access and Affordability: As AI-driven medicine delivery develops, providing universal access to these breakthroughs will become increasingly important. To achieve this, it will be necessary to address healthcare inequities and identify approaches to

make AI-enhanced healthcare accessible and cheap for everybody.

Conclusion

AI-driven drug delivery systems are revolutionizing the healthcare and pharmaceutical industries by enhancing precision, efficiency, and personalized treatment. Machine learning algorithms and models have been instrumental in optimizing drug delivery by analyzing complex datasets to identify the most effective formulations, dosages, and administration routes. This not only improves therapeutic outcomes, but also minimizes adverse effects, enhancing patient safety. The AI application in personalized medicine and targeted drug delivery is a game-changer, as it tailors treatments to individual patient characteristics, including genetics and disease progression. This paradigm shift has the potential to significantly improve patient outcomes, particularly in complex diseases where one-size-fits-all approaches fall short. Smart drug delivery devices empowered by AI add another layer of sophistication to drug administration, monitoring patient responses in real-time, adjusting dosages, and providing valuable insights to healthcare providers. This leads to continuous care and adjustments to treatment plans, leading to better long-term results. AI has the capability to revolutionize the drug development process by identifying promising compounds and predicting their behavior, expediting the discovery of new pharmaceuticals. Robotics and automation, facilitated by AI, streamlining drug manufacturing and distribution processes reduce human error, increase efficiency, and ensure high-degree accuracy. Reliable data sources are crucial for the success of AI-driven drug delivery systems. Real-world case studies and clinical applications

demonstrate the practical benefits of AI in drug delivery, from enhanced cancer treatments to more effective management of chronic diseases. Despite challenges and considerations in implementing AI-driven drug delivery, the prospects and advancements in AI-driven drug delivery systems are bright. From nanoscale drug carriers to highly sophisticated AI-driven treatment plans, the field is poised for continuous growth and innovation, benefiting patients and healthcare systems alike.

ORCID

Francis-Dominic Makong Ekpan

<https://orcid.org/0009-0009-4822-7005>

Merit Oluchi Ori

<https://orcid.org/0009-0005-9259-5842>

Humphrey Sam Samuel

<https://orcid.org/0009-0001-7480-4234>

Odi Peter Egwuatu

<https://orcid.org/0009-0004-0662-9077>

References

1. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design, *Pharmaceutics*; 2023 Jul 10; 15(7):1916. [Crossref], [Google Scholar], [Publisher]
2. Gerke S, Minssen T, Cohen G. Ethical and legal challenges of artificial intelligence-driven healthcare, *In Artificial intelligence in healthcare* ; 2020 Jan 1 (pp. 295-336); Academic Press. [Crossref], [Google Scholar], [Publisher]
3. Pesapane F, Bracchi DA, Mulligan JF, Linnikov A, Maslennikov O, Lanzavecchia MB, Tantrige P, Stasolla A, Biondetti P, Giuggioli PF, Cassano E. Legal and regulatory framework for AI solutions in healthcare in Eu, us, China, and Russia: new scenarios after a pandemic, *Radiation*; 2021 Oct 15; 1(4):261-76. [Crossref], [Google Scholar], [Publisher]

4. Arcaya MC, Arcaya AL, Subramanian SV. Inequalities in health: definitions, concepts, and theories, *Global health action*; 2015 Dec 1; 8(1):27106. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
5. Hardman TC, Aitchison R, Scaife R, Edwards J, Slater G. The future of clinical trials and drug development: 2050, *Drugs in Context*; 2023; 12. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
6. Jiang J, Ma X, Ouyang D, Williams III RO. Emerging artificial intelligence (ai) technologies used in the development of solid dosage forms, *Pharmaceutics*; 2022 Oct 22; 14(11):2257. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
7. Chavda V, Anand K, Apostolopoulos V, editors. *Bioinformatics Tools for Pharmaceutical Drug Product Development*; John Wiley & Sons; 2023 Mar 14. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
8. Gavas S, Quazi S, Karpiński TM. Nanoparticles for cancer therapy: current progress and challenges, *Nanoscale research letters*; 2021 Dec 5; 16(1):173. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
9. Lin Z, Chou WC, Cheng YH, He C, Monteiro-Riviere NA, Riviere JE. Predicting nanoparticle delivery to tumors using machine learning and artificial intelligence approaches, *International journal of nanomedicine*; 2022 Mar 24:1365-79. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
10. Magill E, Demartis S, Gavini E, Permana AD, Thakur RR, Adrianto MF, Waite D, Glover K, Picco CJ, Korelidou A, Detamornrat U. Solid implantable devices for sustained drug delivery, *Advanced Drug Delivery Reviews*; 2023 Jun 8:114950. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
11. Chavda VP, Bezbaruah R, Dolia S, Shah N, Verma S, Savale S, Ray S. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update, *Process Biochemistry*; 2023 Jan 31. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
12. Elumalai K, Srinivasan S, Shanmugam A. Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment, *Biomedical Technology*; 2024 Mar 1; 5:109-22. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
13. Bodenstedt S, Wagner M, Müller-Stich BP, Weitz J, Speidel S. Artificial intelligence-assisted surgery: potential and challenges, *Visceral Medicine*; 2020 Dec 4; 36(6):450-5. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
14. H.S. Samuel and E.E. Etim. Review on ChatGPT: History, Applications and Limitations in Chemistry. *Phys Sci & Biophys J* 2023, 7(2): 000263. DOI: 10.23880/psbj-16000263
15. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development, *Nature reviews Drug discovery*; 2019 Jun; 18(6):463-77. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
16. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design, *Pharmaceutics*; 2023 Jul 10; 15(7):1916. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
17. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of ai in drug discovery: challenges, opportunities, and strategies, *Pharmaceutics*; 2023 Jun 18; 16(6):891. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
18. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence, *Nature medicine*; 2019 Jan; 25(1):44-56. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
19. Suhail M, Khan A, Rahim MA, Naeem A, Fahad M, Badshah SF, Jabar A, Janakiraman AK. Micro and nanorobot-based drug delivery: an overview, *Journal*

- of Drug Targeting; 2022 Apr 21; 30(4):349-58. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
20. Wang Y, Shen J, Handschuh-Wang S, Qiu M, Du S, Wang B. Microrobots for Targeted Delivery and Therapy in Digestive System, *ACS nano*; 2022 Dec 19; 17(1):27-50. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
21. Haleem A, Javaid M, Singh RP, Suman R. Telemedicine for healthcare: Capabilities, features, barriers, and applications, *Sensors international*; 2021 Jan 1; 2:100117. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
22. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries, *Molecular diversity*; 2021 Oct 23:1-21. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
23. You Y, Lai X, Pan Y, Zheng H, Vera J, Liu S, Deng S, Zhang L. Artificial intelligence in cancer target identification and drug discovery, *Signal Transduction and Targeted Therapy*; 2022 May 10; 7(1):156. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
24. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design; *Pharmaceutics*; 2023 Jul 10; 15(7):1916. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
25. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of artificial intelligence for computer-assisted drug discovery, *Chemical reviews*; 2019 Jul 11; 119(18):10520-94. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
26. Zador AM. A critique of pure learning and what artificial neural networks can learn from animal brains, *Nature communications*; 2019 Aug 21; 10(1):3770. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
27. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of ai in drug discovery: challenges, opportunities, and strategies, *Pharmaceutics*; 2023 Jun 18; 16(6):891. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
28. Santa Maria Jr JP, Wang Y, Camargo LM. Perspective on the challenges and opportunities of accelerating drug discovery with artificial intelligence, *Frontiers in Bioinformatics*; 2023 Feb 23; 3:1121591. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
29. Sharma R, Shishodia A, Gunasekaran A, Min H, Munim ZH. The role of artificial intelligence in supply chain management: mapping the territory, *International Journal of Production Research*; 2022 Dec 17; 60(24):7527-50. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
30. Hohma E, Boch A, Trauth R, Lütge C. Investigating accountability for Artificial Intelligence through risk governance: A workshop-based exploratory study, *Frontiers in Psychology*; 2023 Jan 25; 14:1073686. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
31. Wolff J, Pauling J, Keck A, Baumbach J. Systematic review of economic impact studies of artificial intelligence in health care, *Journal of Medical Internet Research*; 2020; 22(2):e16866. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
32. Sahu A, Mishra J, Kushwaha N. Artificial intelligence (AI) in drugs and pharmaceuticals, *Combinatorial Chemistry & High Throughput Screening*; 2022 Sep 1; 25(11):1818-37. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
33. Schork NJ. Artificial intelligence and personalized medicine, *Precision medicine in Cancer therapy*; 2019:265-83. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
34. Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development, *Drug discovery today*; 2021 Jan; 26(1):80. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]
35. Zhang Y, Hu Y, Jiang N, Yetisen AK. Wearable artificial intelligence biosensor

networks, *Biosensors and Bioelectronics*; 2023 Jan 1; 219:114825. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

36. Kuziemy C, Maeder AJ, John O, Gogia SB, Basu A, Meher S, Ito M. Role of artificial intelligence within the telehealth domain, *Yearbook of medical informatics*; 2019 Aug; 28(01):035-40. [[Google Scholar](#)], [[Publisher](#)]

37. Stasevych M, Zvarych V. Innovative robotic technologies and artificial intelligence in pharmacy and medicine:

paving the way for the future of health care—a review, *Big Data and Cognitive Computing*; 2023 Aug 30; 7(3):147.

[[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

38. Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial Intelligence Applied to clinical trials: opportunities and challenges, *Health and Technology*; 2023 Mar; 13(2):203-13. [[Crossref](#)], [[Google Scholar](#)], [[Publisher](#)]

How to cite this article:

Francis-Dominic Makong Ekpan, Merit Oluchi Ori, Humphrey Sam Samuel, Odii Peter Egwuatu. The Synergy of AI and Drug Delivery: A Revolution in Healthcare. *International Journal of Advanced Biological and Biomedical Research*, 2024, 12(1):44-66.

Link: https://www.ijabbr.com/article_709788.html